The posts contained on this account are my own opinions and are not recommendations or advise to buy or sell any security, stocks or other investments. These posts are for entertainment purposes only and are not considered to be facts or truth.
Recent OGEN News
- Oragenics Develops Automated Intranasal Device for Treating Concussed Patients • GlobeNewswire Inc. • 06/27/2024 12:30:40 PM
- Oragenics, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 06/26/2024 08:47:15 PM
- Oragenics, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 06/25/2024 12:30:00 PM
- Oragenics, Inc. Announces Proposed Public Offering • GlobeNewswire Inc. • 06/24/2024 10:43:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:00:24 PM
- Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance • GlobeNewswire Inc. • 06/20/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 01:27:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 12:00:17 PM
- Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer • GlobeNewswire Inc. • 05/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 12:00:41 PM
- Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine • GlobeNewswire Inc. • 05/17/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 12:00:22 PM
- Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial • GlobeNewswire Inc. • 05/16/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 05:00:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:14:33 PM
- Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards • Business Wire • 04/19/2024 09:50:00 PM
- Oragenics, Inc. Files 10K and Provides Company Update • Business Wire • 04/01/2024 01:05:00 PM
- Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion • Business Wire • 03/18/2024 11:00:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 03/06/2024 09:24:29 PM
- Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion • Business Wire • 03/05/2024 12:45:00 PM
- Oragenics Announces Closing of Public Offering • Business Wire • 03/01/2024 09:04:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/29/2024 09:41:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:03:04 PM
- Oragenics Announces Pricing of Public Offering • Business Wire • 02/28/2024 02:25:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM